{"url_path":"/sec/sprb/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-220648-index.html","accession_number":"0001193125-26-220648","cik":"0001683553","ticker":"SPRB","issuer_name":"SPRUCE BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-220648-index.html","primary_entity_key":"0001683553","primary_entity_name":"SPRUCE BIOSCIENCES, INC."},"word_count":287,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn May 13, 2026, Spruce Biosciences, Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe Company also reported cash and cash equivalents of $107.3 million as of April 30, 2026. This estimate is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of April 30, 2026. Accordingly, the unaudited preliminary cash and cash equivalents balance set forth above reflects the Company’s preliminary estimate with respect to such information, based on information currently available to management, and may vary from its actual financial position as of April 30, 2026. The information presented herein should not be considered a substitute for the financial information the Company files with the U.S. Securities and Exchange Commission. The Company has no intention or obligation to update preliminary estimates of its cash and cash equivalents set forth above.\n\nAll of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}